DrugBiological
Lirilumab clinical trials
Also written BMS-986015 and IPH-2102.
- studies test it
- 8
- open now
- 1
- in phase 3
- 0
- first study started
- 2012
Keep track of what changes. Save the lirilumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
8 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 5
Bristol-Myers Squibb (3) · M.D. Anderson Cancer Center (2) · Dana-Farber Cancer Institute (1) · PrECOG, LLC. (1) · Gustave Roussy, Cancer Campus, Grand Paris (1)
Often tested with
Tested in the same studies.
Nivolumab (4) · Ipilimumab (2) · Rituximab (1) · Urelumab (1) · Ribociclib (1) · Topotecan (1) · Temozolomide (1) · Everolimus (1)
Studies
Open first, then newest update. How each study uses lirilumab is read from its arms, and is right about nine times in ten.
Testing it · 8
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT02813135Written as Lirilumab
- Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHNActive, not recruitingPhase 2Dana-Farber Cancer InstituteNCT03341936Written as Lirilumab
- Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder CancerCompletedPhase 1PrECOG, LLC.NCT03532451Written as Nivolumab/Lirilumab
- A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid TumorsCompletedPhase 1Bristol-Myers SquibbNCT03203876Written as Lirilumab
- Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) PatientsCompletedPhase 2M.D. Anderson Cancer CenterNCT02481297Written as Lirilumab
- Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid LeukemiaTerminatedPhase 2M.D. Anderson Cancer CenterNCT02399917Written as Lirilumab
- A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple MyelomaCompletedPhase 1Bristol-Myers SquibbNCT02252263Written as Lirilumab
- Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced TumorCompletedPhase 1Bristol-Myers SquibbNCT01750580Written as Lirilumab
Given in every arm · 4 — lirilumab is usual care beside what is tested
- An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple MyelomaCompletedPhase 1/2Bristol-Myers SquibbNCT01592370Written as Lirilumab
- A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid TumorsCompletedPhase 1/2Bristol-Myers SquibbNCT01714739Written as Lirilumab
- A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)TerminatedPhase 1/2Incyte CorporationNCT03347123Written as Lirilumab
- Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)TerminatedPhase 2M.D. Anderson Cancer CenterNCT02599649Written as Lirilumab
Codes
What other systems call lirilumab · ClinicalTrials.gg INT001953
- UNII (FDA) S9XDI9W918LIRILUMABConfirmed FDA, Wikidata
- Wikidata Q6557650LirilumabConfirmed FDA, Wikidata
- NCI Thesaurus C103820LirilumabOne source FDA
- DrugBank DB11754One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | S9XDI9W918 | LIRILUMAB | Confirmed FDA, Wikidata |
| Wikidata | Q6557650 | Lirilumab | Confirmed FDA, Wikidata |
| NCI Thesaurus | C103820 | Lirilumab | One source FDA |
| DrugBank | DB11754 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.